home / stock / invvy / invvy news


INVVY News and Press, Indivior PLC ADR From 04/28/22

Stock Information

Company Name: Indivior PLC ADR
Stock Symbol: INVVY
Market: OTC
Website: indivior.com

Menu

INVVY INVVY Quote INVVY Short INVVY News INVVY Articles INVVY Message Board
Get INVVY Alerts

News, Short Squeeze, Breakout and More Instantly...

INVVY - Indivior PLC 2022 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Indivior PLC in conjunction with their 2022 Q1 earnings call. For further details see: Indivior PLC 2022 Q1 - Results - Earnings Call Presentation

INVVY - Indivior PLC ADR Non-GAAP EPS of $0.06, revenue of $207M; on track to achieve FY 2022 guidance

Indivior PLC ADR press release (OTCPK:INVVY): Q1 Non-GAAP EPS of $0.06. Revenue of $207M (+15.0% Y/Y). On an adjusted basis, Q1 2022 operating profit was $54M (+6% vs. adj. Q1 2021: $51M). FY 2022 guidance issued by Indivior on February 16, 2022, is unchanged. For further details see: I...

INVVY - Indivior Announces Q1 2022 Financial Results

Indivior Announces Q1 2022 Financial Results PR Newswire SLOUGH, U.K. and RICHMOND, Va. , April 28, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending March 31, 2022 . The earnings releas...

INVVY - Indivior Statement on Nationwide Increases in Fentanyl-Related Mass-Overdose Events

Indivior Statement on Nationwide Increases in Fentanyl-Related Mass-Overdose Events PR Newswire Expanding access to medication to treat opioid use disorder is a critical part of the solution RICHMOND, Va. , April 12, 2022 /PRNewswire/ -- Indivior ...

INVVY - Indivior posts data from buprenorphine-fentanyl trial to treat respiratory depression

Indivior (OTCPK:INVVY) announced modeling data testing the interaction between buprenorphine, a treatment for opioid use disorder (OUD), and fentanyl, a synthetic opioid, to check how buprenorphine can reduce fentanyl-induced respiratory depression. The company said the modeling data ind...

INVVY - Indivior Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users

Indivior Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users PR Newswire Data available online and in an upcoming print issue of JCI Insight, a peer-reviewed journal RICHMOND, Va. , ...

INVVY - Indivior to Commence Formal Shareholder Consultations on Additional US Listing

Indivior to Commence Formal Shareholder Consultations on Additional US Listing PR Newswire RICHMOND, Va. , March 31, 2022 /PRNewswire/ -- Indivior PLC, (LON: INDV) today announced that further to its announcement on February 16, 2022 , it is comm...

INVVY - Indivior PLC (INVVY) CEO Mark Crossley on Q4 2021 Results - Earnings Call Transcript

Indivior PLC (INVVY) Q4 2021 Results Earnings Conference Call February 16, 2022, 08:00 AM ET Company Participants Mark Crossley - Chief Executive Officer Ryan Preblick - Chief Financial Officer Christian Heidbreder - Chief Scientific Officer Conference Call Participants Christian Glennie - St...

INVVY - Indivior PLC 2022 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Indivior PLC in conjunction with their 2022 Q4 earnings call. For further details see: Indivior PLC 2022 Q4 - Results - Earnings Call Presentation

INVVY - Indivior PLC ADR Non-GAAP EPS of $0.03, revenue of $222M

Indivior PLC ADR press release (OTCPK:INVVY): Q4 Non-GAAP EPS of $0.03. Revenue of $222M (+20.0% Y/Y). For further details see: Indivior PLC ADR Non-GAAP EPS of $0.03, revenue of $222M

Previous 10 Next 10